Provided by Tiger Trade Technology Pte. Ltd.

SELLAS Life Sciences Group Inc.

3.81
+0.08002.14%
Post-market: 3.830.0200+0.52%19:59 EST
Volume:4.10M
Turnover:15.27M
Market Cap:647.70M
PE:-13.55
High:3.84
Open:3.77
Low:3.62
Close:3.73
52wk High:5.18
52wk Low:0.9516
Shares:170.00M
Float Shares:170.00M
Volume Ratio:0.71
T/O Rate:2.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2813
EPS(LYR):-0.5046
ROE:-84.33%
ROA:-44.90%
PB:14.19
PE(LYR):-7.55

Loading ...

Sellas Life Sciences Group stellt neue Therapien für AML mit Fokus auf Galinpepimut-S und SLS009 vor

Reuters
·
Feb 04

The machine economy: AI will benefit crypto, or break it | Opinion

cryptonews
·
Jan 30

Mixed options sentiment in Sellas Life Sciences with shares down 1.75%

TIPRANKS
·
Jan 23

Amentum announces successful rollout of SLS rocket, Orion spacecraft from VAB

TIPRANKS
·
Jan 20

Sellas Life Sciences enters agreement with IMPACT-AML

TIPRANKS
·
Jan 14

Sellas Life Sciences Partners with IMPACT-AML to Expand SLS009 Trials into Europe

Reuters
·
Jan 14

Sellas Life Sciences Group Inc - Sls009 U.S. Enrollment Planned for Q1 2026, Europe Enrollment Anticipated in Q2 2026

THOMSON REUTERS
·
Jan 14

Sellas Life Sciences Enters Agreement With Impact-Aml to Expand Sls009 Clinical Program Into Europe

THOMSON REUTERS
·
Jan 14

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

GlobeNewswire
·
Jan 14

Sellas Life Sciences Raises $26.5 Million from Warrant Exercises

Reuters
·
Jan 08

A Look At SELLAS Life Sciences Group (SLS) Valuation As REGAL Phase 3 Trial Nears Final Event Trigger

Simply Wall St.
·
Jan 06

Social Buzz: Wallstreetbets Stocks Advance Premarket Monday; SELLAS Life Sciences Group, Chevron to Open Higher

MT Newswires Live
·
Jan 05

SELLAS Life Sciences Stock Is Surging Higher: What's Going On?

Benzinga_recent_news
·
Dec 30, 2025

SELLAS Life Sciences Group Up Nearly 17%, on Track for Highest Close Since February 2023 -- Data Talk

Dow Jones
·
Dec 30, 2025

Sellas Life Sciences Says 72 Deaths Have Occurred in Phase 3 Acute Myeloid Leukemia Trial

MT Newswires Live
·
Dec 29, 2025

Sellas Life Sciences Reports Progress in Phase 3 REGAL Trial of Galinpepimut-S for AML

Reuters
·
Dec 29, 2025

Sellas Life Sciences Provides Update on Pivotal Phase 3 Regal Trial of Galinpepimut-S (Gps) in Acute Myeloid Leukemia (Aml)

THOMSON REUTERS
·
Dec 29, 2025

New NASA Chief Vows: Moon Return Within Trump's Term

Stock News
·
Dec 28, 2025

Key Reasons Behind Jared Isaacman's Appointment as NASA Administrator and Analysis of the Athena Plan

Deep News
·
Dec 21, 2025

SELLAS Life Sciences Group (SLS): Valuation Check After Positive Phase 2 Data for SLS009 in AML

Simply Wall St.
·
Dec 10, 2025